Halozyme (HALO) Stock Price & Analysis
HALO Stock Chart & Stats
- Day’s Range
- MXN 1,868.50 - MXN 2,370.00
- 52-Week Range
- MXN 337.60 - MXN 2,460.00
- Previous Close
- MXN 2,370.00
- Volume
- 0
- Average Volume (3M)
- 204
- Market Cap
- MXN 219.49B
- Enterprise Value
- MXN 15.71B
- Total Cash (Recent Filing)
- MXN 1.07B
- Total Debt (Recent Filing)
- MXN 3.25B
- Price to Earnings (P/E)
- 24.7
- Beta
- 0.37
- Next Earnings
- Feb 23, 2027 (Est.)
- EPS Estimate
- 47.67
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Royalty Portfolio Growth
Broad-based royalty growth across multiple commercial products demonstrates that Halozyme is benefiting from expanding adoption of ENHANZE-enabled therapies. Diversification across partners and indications supports recurring revenue durability and reduces reliance on any single product over the next several quarters.
ENHANZE Pipeline Expansion
Expanded partner commitments and a growing clinical pipeline strengthen Halozyme’s platform economics by creating additional opportunities for milestones and future royalties. Multiple programs advancing toward commercialization can extend revenue growth and reinforce ENHANZE’s strategic value to drug developers.
Raised Growth And Margin Outlook
Management’s raised outlook combines rapid revenue and royalty growth with a very high projected adjusted EBITDA margin, indicating strong operating leverage in the licensing model. Sustained profitability and cash generation should support continued platform investment and capital allocation flexibility.
Bears Say
High Leverage And Negative Equity
Elevated debt alongside negative shareholder equity reduces financial flexibility and makes the capital structure more sensitive to any weakening in operating performance. Although cash generation is strong, substantial leverage can constrain investment choices and increase refinancing or repayment pressure.
U.S. Patent Litigation Risk
Adverse U.S. patent rulings create a lasting risk to the protection supporting Halozyme’s royalty economics, with the appeal process expected to continue likely until 2028. Unfavorable outcomes could weaken bargaining power, alter royalty durability, or increase litigation-related costs.
Potential Royalty Rate Pressure
Low starting royalty rates and possible patent-linked step-downs can reduce the economic contribution of newer partnerships compared with established agreements. As the portfolio expands, deal-level variability may make future royalty growth less profitable and less predictable than headline product adoption suggests.
Halozyme News
HALO FAQ
What was Halozyme’s price range in the past 12 months?
What is Halozyme’s market cap?
When is Halozyme’s upcoming earnings report date?
How were Halozyme’s earnings last quarter?
Is Halozyme overvalued?
Does Halozyme pay dividends?
What is Halozyme’s EPS estimate?
How many shares outstanding does Halozyme have?
What happened to Halozyme’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Halozyme?
What is the TipRanks Smart Score and how is it calculated?
Halozyme Stock Smart Score
Company Description
Halozyme
Halozyme Therapeutics, Inc. is a biopharmaceutical company headquartered in San Diego, California, with operations spanning the United States, Switzerland, Ireland, Belgium, Japan, and other international markets. At its core is the proprietary ENHANZE drug delivery platform, which utilizes a patented recombinant human hyaluronidase enzyme (rHuPH20). This innovative technology significantly enhances the subcutaneous (under-the-skin) administration of a diverse range of injectable medicines. This includes complex biologics such as monoclonal antibodies, various other therapeutic molecules, smaller drug compounds, and even fluids. The company's leading product, Hylenex recombinant, is an rHuPH20 formulation specifically designed to facilitate subcutaneous fluid delivery for hydration. It also plays a crucial role in improving the dispersion and absorption of other injected drugs during subcutaneous urography, and aids in the resorption of radiopaque agents. Halozyme also offers several key therapeutics leveraging its platform, including Perjeta, RITUXAN HYCELA, and MabThera SC, which are used to treat non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL). RITUXAN SC is another offering for CLL patients, while HYQVIA addresses various immunodeficiency disorders. Their development pipeline boasts numerous investigational drugs, such as Tecentriq for non-small cell lung cancer, OCREVUS for multiple sclerosis, and DARZALEX, which targets amyloidosis, smoldering myeloma, and multiple myeloma. Other pipeline candidates include nivolumab for solid tumors, ARGX-113 (a human neonatal Fc receptor), ARGX-117 for autoimmune diseases, and BMS-986179, an anti-CD-73 antibody. Halozyme maintains extensive collaborations with prominent pharmaceutical companies like F. Hoffmann-La Roche, Pfizer Inc., Janssen Biotech, Inc., AbbVie, Inc., Eli Lilly and Company, Bristol-Myers Squibb Company, Alexion Pharma Holding, ARGENX BVBA, and Horizon Therapeutics plc. They also partner with research institutions such as the National Institute of Allergy and Infectious Diseases, the Centre for the AIDS Programme of Research in South Africa, and ViiV Healthcare Limited, particularly focusing on both small and large molecule targets for the treatment and prevention of HIV. The company was established in 1998.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Helen I. Torley
- Employees
- 423
- Website
- www.halozyme.com
- Address
- 12390 El Camino Real, San Diego, CA, 92130, US
Halozyme (HALO) Earnings & Revenues
HALO Company Deck
HALO Earnings Call
Earnings Call SentimentPositive
The call was strongly positive, supported by record revenue and royalty results, raised 2026 guidance, broad-based commercial product growth, expanding partner agreements, pipeline advancement and progress with Hypercon and Aerocon. The main negative items were higher operating expenses, adverse initial U.S. patent rulings, ongoing litigation and development and collaboration-revenue timing uncertainties, but these were outweighed by the reported operating momentum and growth opportunities.
View all MX:HALO earnings summariesHALO Net sales Breakdown
- 54.01% Royalties
- 36.28% Product sales
- 9.71% Revenues under collaborative agreements
HALO Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 12 | 3 | 7 |
| Technical Analysis | 3 | 3 | 4 |
| Moving Averages | 9 | 0 | 3 |
